{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T03:49:49Z","timestamp":1784864989481,"version":"3.55.0"},"reference-count":114,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,20]],"date-time":"2017-12-20T00:00:00Z","timestamp":1513728000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","croh-online.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.critrevonc.2017.11.016","type":"journal-article","created":{"date-parts":[[2017,12,6]],"date-time":"2017-12-06T06:26:58Z","timestamp":1512541618000},"page":"74-89","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["A question of class: Treatment options for patients with relapsed and\/or refractory multiple myeloma"],"prefix":"10.1016","volume":"121","author":[{"given":"Gordon","family":"Cook","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Zweegman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda-Victoria","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Suzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.critrevonc.2017.11.016_bib0005","doi-asserted-by":"crossref","first-page":"7896","DOI":"10.1158\/0008-5472.CAN-05-0506","article-title":"Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells","volume":"65","author":"Altun","year":"2005","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2017.11.016_bib0010","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1200\/JCO.2011.37.8919","article-title":"The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma","volume":"30","author":"Anderson","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2017.11.016_bib0015","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","article-title":"Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du My\u00e9lome","volume":"109","author":"Avet-Loiseau","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2017.11.016_bib0020","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1182\/blood-2016-03-707596","article-title":"Carfilzomib significantly improves the progression free survival of high-risk patients in multiple myeloma","volume":"128","author":"Avet-Loiseau","year":"2016","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.critrevonc.2017.11.016_bib0025","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/leu.2014.27","article-title":"Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy","volume":"28","author":"Berenson","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2017.11.016_bib0030","series-title":"Guidelines for the Diagnosis and Management of Multiple Myeloma","author":"Bird","year":"2014"},{"issue":"6","key":"10.1016\/j.critrevonc.2017.11.016_bib0035","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3324\/haematol.2012.075051","article-title":"Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials","volume":"98","author":"Bringhen","year":"2013","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.critrevonc.2017.11.016_bib0040","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1097\/CAD.0000000000000285","article-title":"Salvage therapy with bortezomib and dexamethasone in elderly patients with relapsed\/refractory multiple myeloma","volume":"26","author":"Castelli","year":"2015","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.critrevonc.2017.11.016_bib0045","series-title":"Highlights of Prescribing Information","author":"Celgene Corporation POMALYST","year":"2016"},{"key":"10.1016\/j.critrevonc.2017.11.016_bib0050","series-title":"Highlights of Prescribing Information","author":"Celgene Corporation Revlimid","year":"2013"},{"key":"10.1016\/j.critrevonc.2017.11.016_bib0055","series-title":"Highlights of Prescribing Information","author":"Celgene Corporation Thalomid","year":"2014"},{"key":"10.1016\/j.critrevonc.2017.11.016_bib0060","series-title":"Imnovid: Summary of Product Characteristics","author":"Celgene Europe Ltd","year":"2016"},{"key":"10.1016\/j.critrevonc.2017.11.016_bib0065","series-title":"Revlimid: Summary of Product Characteristics","author":"Celgene Europe Ltd","year":"2016"},{"key":"10.1016\/j.critrevonc.2017.11.016_bib0070","series-title":"Thalomid: Summary of Product Characteristics","author":"Celgene Europe Ltd","year":"2016"},{"issue":"22","key":"10.1016\/j.critrevonc.2017.11.016_bib0075","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1182\/blood.V128.22.3313.3313","article-title":"Daratumumab, bortezomib and dexamethasone versus bortezomib and dexamethasone alone for relapsed or refractory multiple myeloma based on prior treatment exposure: updated efficacy analysis of CASTOR","volume":"128","author":"Chanan-Khan","year":"2016","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.critrevonc.2017.11.016_bib0080","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1182\/blood.V126.23.508.508","article-title":"Open-label, multicenter, phase 1b study of daratumumab in combination with pomalidomide and dexamethasone in patients with at least 2 lines of prior therapy and relapsed or relapsed and refractory multiple myeloma","volume":"126","author":"Chari","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2017.11.016_bib0085","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/leu.2013.247","article-title":"IMWG consensus on risk stratification in multiple myeloma","volume":"28","author":"Chng","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2017.11.016_bib0090","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2016.390","article-title":"Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR","author":"Chng","year":"2017","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.critrevonc.2017.11.016_bib0095","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3816\/CLM.2008.n.016","article-title":"An observational, retrospective analysis of retreatment with bortezomib for multiple myeloma","volume":"8","author":"Conner","year":"2008","journal-title":"Clin. Lymphoma Myeloma"},{"issue":"7","key":"10.1016\/j.critrevonc.2017.11.016_bib0100","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1016\/S2352-3026(16)30049-7","article-title":"The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT\/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial","volume":"3","author":"Cook","year":"2016","journal-title":"Lancet Haematol."},{"issue":"4","key":"10.1016\/j.critrevonc.2017.11.016_bib0105","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/bmt.2015.307","article-title":"Evolving paradigms in the treatment of relapsed\/refractory multiple myeloma: increased options and increased complexity","volume":"51","author":"Cornell","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.critrevonc.2017.11.016_bib0110","series-title":"Highlights of Prescribing Information","author":"Darzalex","year":"2015"},{"key":"10.1016\/j.critrevonc.2017.11.016_bib0115","series-title":"Summary of Product Characteristics","author":"Darzalex","year":"2016"},{"issue":"13","key":"10.1016\/j.critrevonc.2017.11.016_bib0120","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1158\/0008-5472.CAN-06-4086","article-title":"Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome","volume":"67","author":"Demo","year":"2007","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.critrevonc.2017.11.016_bib0125","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1023\/A:1011132808904","article-title":"Thalidomide and dexamethasone combination for refractory multiple myeloma","volume":"12","author":"Dimopoulos","year":"2001","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2017.11.016_bib0130","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/sj.thj.6200326","article-title":"Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma","volume":"5","author":"Dimopoulos","year":"2004","journal-title":"Hematol. J."},{"issue":"21","key":"10.1016\/j.critrevonc.2017.11.016_bib0135","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.critrevonc.2017.11.016_bib0140","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/leu.2009.147","article-title":"Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"23","author":"Dimopoulos","year":"2009","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.critrevonc.2017.11.016_bib0145","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1038\/leu.2010.175","article-title":"Treatment of patients with relapsed\/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies","volume":"24","author":"Dimopoulos","year":"2010","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.critrevonc.2017.11.016_bib0150","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol."},{"issue":"14","key":"10.1016\/j.critrevonc.2017.11.016_bib0155","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2017.11.016_bib0160","series-title":"16th International Myeloma Workshop","article-title":"Overall survival of patients with relapsed or refractory multiple myeloma treated with carfilzomib and dexamethasone versus bortezomib and dexamethasone in the randomized phase 3 ENDEAVOR trial","author":"Dimopoulos","year":"2017"},{"key":"10.1016\/j.critrevonc.2017.11.016_bib0165","series-title":"DARZALEX: Summary of Opinion (post Authorisation)","author":"European Medicines Agency","year":"2017"},{"key":"10.1016\/j.critrevonc.2017.11.016_bib0170","series-title":"Highlights of Prescribing Information","author":"Farydak","year":"2016"},{"key":"10.1016\/j.critrevonc.2017.11.016_bib0175","series-title":"Summary of Product Characteristics","author":"Farydak","year":"2016"},{"key":"10.1016\/j.critrevonc.2017.11.016_bib0180","series-title":"Ninlaro: Statistical Review and Evaluation","author":"Food and Drug Administration","year":"2015"},{"issue":"6","key":"10.1016\/j.critrevonc.2017.11.016_bib0185","first-page":"2297","article-title":"Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events","volume":"31","author":"Fukushima","year":"2011","journal-title":"Anticancer Res."},{"issue":"20","key":"10.1016\/j.critrevonc.2017.11.016_bib0190","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1200\/JCO.2011.37.4918","volume":"30","author":"Garderet","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2017.11.016_bib0195","article-title":"A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)","author":"Hajek","year":"2016","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.critrevonc.2017.11.016_bib0200","doi-asserted-by":"crossref","first-page":"e437","DOI":"10.1016\/S1470-2045(12)70259-0","article-title":"Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review","volume":"13","author":"Hamaker","year":"2012","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2017.11.016_bib0205","doi-asserted-by":"crossref","first-page":"E86","DOI":"10.1002\/ajh.23967","article-title":"The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit","volume":"90","author":"Harrison","year":"2015","journal-title":"Am. J. Hematol."},{"issue":"21","key":"10.1016\/j.critrevonc.2017.11.016_bib0210","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1182\/blood.V122.21.1969.1969","article-title":"MM-005: a phase 1 trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and\/or refractory multiple myeloma (RRMM)","volume":"122","author":"Hofmeister","year":"2013","journal-title":"Blood"},{"issue":"3-4","key":"10.1016\/j.critrevonc.2017.11.016_bib0215","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1159\/000322866","article-title":"Bortezomib retreatment in relapsed multiple myeloma \u2013 results from a retrospective multicentre survey in Germany and Switzerland","volume":"79","author":"Hrusovsky","year":"2010","journal-title":"Oncology"},{"issue":"3","key":"10.1016\/j.critrevonc.2017.11.016_bib0220","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s12185-016-2073-4","article-title":"Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs","volume":"104","author":"Ito","year":"2016","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.critrevonc.2017.11.016_bib0225","article-title":"eal-world prospective evaluation of different geriatric assessment tools in unselected elderly patients with symptomatic myeloma","volume":"4242","author":"Kastritis","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2017.11.016_bib0230","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.clml.2013.03.016","article-title":"Histone deacetylase inhibitors in multiple myeloma: rationale and evidence for their use in combination therapy","volume":"13","author":"Kaufman","year":"2013","journal-title":"Clin. Lymphoma Myeloma Leukemia"},{"issue":"5","key":"10.1016\/j.critrevonc.2017.11.016_bib0235","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3324\/haematol.2011.044271","article-title":"Thalidomide versus dexamethasone for the treatment of relapsed and\/or refractory multiple myeloma: results from OPTIMUM, a randomized trial","volume":"97","author":"Kropff","year":"2012","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.critrevonc.2017.11.016_bib0240","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1053\/j.seminhematol.2012.04.003","article-title":"The immunoproteasome as a target in hematologic malignancies","volume":"49","author":"Kuhn","year":"2012","journal-title":"Semin. Hematol."},{"issue":"5","key":"10.1016\/j.critrevonc.2017.11.016_bib0245","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2017.11.016_bib0250","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/leu.2011.196","article-title":"Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter International Myeloma Working Group study","volume":"26","author":"Kumar","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2017.11.016_bib0255","series-title":"Highlights of Prescribing Information","author":"Kyprolis","year":"2015"},{"key":"10.1016\/j.critrevonc.2017.11.016_bib0260","series-title":"Summary of Product Characteristics","author":"Kyprolis","year":"2016"},{"issue":"19","key":"10.1016\/j.critrevonc.2017.11.016_bib0265","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1182\/blood-2015-05-612960","article-title":"How I treat fragile myeloma patients","volume":"126","author":"Larocca","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.critrevonc.2017.11.016_bib0270","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/leu.2015.356","article-title":"Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group","volume":"30","author":"Laubach","year":"2016","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.critrevonc.2017.11.016_bib0275","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2012-09-452375","article-title":"Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide\u2013refractory multiple myeloma: intergroupe Francophone du My\u00e9lome 2009-02","volume":"121","author":"Leleu","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.critrevonc.2017.11.016_bib0280","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1182\/blood-2014-11-612069","article-title":"Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and\/or translocation (4;14): IFM 2010\u201302 trial results","volume":"125","author":"Leleu","year":"2015","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.critrevonc.2017.11.016_bib0285","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.critrevonc.2017.11.016_bib0290","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1182\/blood-2015-06-653261","article-title":"How treat high-risk myeloma","volume":"126","author":"Lonial","year":"2015","journal-title":"Blood"},{"issue":"10027","key":"10.1016\/j.critrevonc.2017.11.016_bib0295","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.critrevonc.2017.11.016_bib0300","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1634\/theoncologist.2014-0042","article-title":"European perspective on multiple myeloma treatment strategiesin 2014","volume":"19","author":"Ludwig","year":"2014","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.critrevonc.2017.11.016_bib0305","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/2040620711432020","article-title":"Safety and efficacy of subcutaneous formulation of bortezomib versus the conventional intravenous formulation in multiple myeloma","volume":"3","author":"Mateos","year":"2012","journal-title":"Therap. Adv. Hematol."},{"issue":"3","key":"10.1016\/j.critrevonc.2017.11.016_bib0310","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/bjh.14263","article-title":"Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed\/refractory multiple myeloma","volume":"175","author":"Mateos","year":"2016","journal-title":"Br. J. Haematol."},{"issue":"22","key":"10.1016\/j.critrevonc.2017.11.016_bib0315","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1182\/blood.V128.22.1150.1150","article-title":"Efficacy of daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory myeloma based on prior lines of therapy: updated analysis of CASTOR","volume":"128","author":"Mateos","year":"2016","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.critrevonc.2017.11.016_bib0320","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1182\/blood-2009-10-163329","article-title":"How I treat elderly patients with myeloma","volume":"116","author":"Mehta","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2017.11.016_bib0325","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.mayocp.2013.01.019","article-title":"Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensusguidelines 2013","volume":"88","author":"Mikhael","year":"2013","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.critrevonc.2017.11.016_bib0330","series-title":"Highlights of Prescribing Information","author":"Millennium Pharmaceuticals Ninlaro","year":"2015"},{"key":"10.1016\/j.critrevonc.2017.11.016_bib0335","series-title":"Highlights of Prescribing Information","author":"Millennium Pharmaceuticals Velcade","year":"2015"},{"issue":"5","key":"10.1016\/j.critrevonc.2017.11.016_bib0340","first-page":"296","article-title":"Panobinostat (Farydak): a novel option for the treatment of relapsed or relapsed and refractory multiple myeloma","volume":"41","author":"Moore","year":"2016","journal-title":"Pharm. Therapeut."},{"issue":"5","key":"10.1016\/j.critrevonc.2017.11.016_bib0345","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol."},{"issue":"Suppl 6","key":"10.1016\/j.critrevonc.2017.11.016_bib0350","doi-asserted-by":"crossref","first-page":"vi133","DOI":"10.1093\/annonc\/mdt297","article-title":"Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Moreau","year":"2013","journal-title":"Ann. Oncol."},{"issue":"20","key":"10.1016\/j.critrevonc.2017.11.016_bib0355","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1200\/JCO.2013.53.0329","volume":"32","author":"Moreau","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2017.11.016_bib0360","article-title":"Analysis of patient outcomes by prior treatment and depth of response in Startus (MM-010), a phase 3b study of pomalidomide plus low-dose dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"1834","author":"Moreau","year":"2015","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.critrevonc.2017.11.016_bib0365","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.critrevonc.2017.11.016_bib0370","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1182\/blood.V128.22.489.489","article-title":"Efficacy of daratumumab, lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone for relapsed or refractory multiple myeloma among patients with 1\u20133 prior lines of therapy based on previous treatment exposure: updated analysis of POLLUX","volume":"128","author":"Moreau","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2017.11.016_bib0375","article-title":"Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study","author":"Moreau","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2017.11.016_bib0380","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdw606","article-title":"Second primary malignancies in multiple myeloma: an overview and IMWG consensus","author":"Musto","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2017.11.016_bib0385","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2016-07-729236","article-title":"Phase 1\/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma","author":"Nijhof","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2017.11.016_bib0390","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.2147\/OTT.S49187","article-title":"An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma","volume":"7","author":"Offidani","year":"2014","journal-title":"Onco Targets Ther."},{"issue":"6","key":"10.1016\/j.critrevonc.2017.11.016_bib0395","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00277-016-2661-7","article-title":"Reduced frequency treatment with bortezomib plus dexamethasone for elderly patients with relapsed and\/or refractory multiple myeloma: a phase 2 study of the Japanese Myeloma Study Group (JMSG-0902)","volume":"95","author":"Ozaki","year":"2016","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.critrevonc.2017.11.016_bib0400","series-title":"American Society of Hematology Annual Meeting","article-title":"Outcome for Older Patients in Stratus (MM-010) a Single-arm, and Phase 3b Study of Pomalidomide Plus Low Dose Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma in","author":"Palumbo","year":"2014"},{"issue":"13","key":"10.1016\/j.critrevonc.2017.11.016_bib0405","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.critrevonc.2017.11.016_bib0410","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2017.11.016_bib0415","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup","volume":"1844","author":"Palumbo","year":"2015","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.critrevonc.2017.11.016_bib0420","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2017.11.016_bib0425","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":"Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma","volume":"24","author":"Quach","year":"2010","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.critrevonc.2017.11.016_bib0430","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2007.14.1853","article-title":"Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma","volume":"26","author":"Rajkumar","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2017.11.016_bib0435","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1182\/blood-2008-12-193458","article-title":"Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13","volume":"114","author":"Reece","year":"2009","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.critrevonc.2017.11.016_bib0440","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2017.11.016_bib0445","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1365-2141.2007.06585.x","article-title":"Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma","volume":"137","author":"Richardson","year":"2007","journal-title":"Br. J. Haematol."},{"issue":"14","key":"10.1016\/j.critrevonc.2017.11.016_bib0450","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1182\/blood-2013-01-481325","article-title":"PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma","volume":"122","author":"Richardson","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2017.11.016_bib0455","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.8018","article-title":"Efficacy and safety of ixazomib plus lenalidomide-dexamethasone (IRd) vs placebo-rd in patients (pts) with relapsed\/refractory multiple myeloma (RRMM) by cytogenetic risk status in the global phase III Tourmaline-M study","volume":"34","author":"Richardson","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2017.11.016_bib0460","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"San Miguel","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2017.11.016_bib0465","first-page":"34","article-title":"A randomized phase 2 study of pomalidomide\/dexamethasone with or without elotuzumab in patients with relapsed\/refractory multiple myeloma","author":"San Miguel","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2017.11.016_bib0470","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","article-title":"Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial","volume":"15","author":"San-Miguel","year":"2014","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2017.11.016_bib0475","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejca.2009.07.006","article-title":"Improved survival among younger but not among older patients with multiple myeloma in the Netherlands, a population-based study since 1989","volume":"46","author":"Schaapveld","year":"2010","journal-title":"Eur. J. Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2017.11.016_bib0480","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1038\/leu.2009.173","article-title":"Proteasome inhibitors in the treatment of multiple myeloma","volume":"23","author":"Shah","year":"2009","journal-title":"Leukemia"},{"issue":"20","key":"10.1016\/j.critrevonc.2017.11.016_bib0485","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1182\/blood-2015-05-643320","article-title":"Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma","volume":"126","author":"Shah","year":"2015","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.critrevonc.2017.11.016_bib0490","first-page":"e315","article-title":"Proteasome inhibitors block Ikaros degradation by lenalidomide in multiple myeloma","volume":"100","author":"Shi","year":"2015","journal-title":"Haematologica"},{"issue":"24","key":"10.1016\/j.critrevonc.2017.11.016_bib0495","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2017.11.016_bib0500","series-title":"Empliciti: Highlights of Prescribing Information","author":"Squibb","year":"2015"},{"key":"10.1016\/j.critrevonc.2017.11.016_bib0505","series-title":"Empliciti: Summary of Product Charateristics","author":"Squibb","year":"2016"},{"issue":"2","key":"10.1016\/j.critrevonc.2017.11.016_bib0510","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2017.11.016_bib0515","series-title":"Summary of Product Characteristics","author":"Takeda Pharma Nilaro","year":"2016"},{"issue":"1","key":"10.1016\/j.critrevonc.2017.11.016_bib0520","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2015.04.008","article-title":"Proteasome inhibitors","volume":"96","author":"Teicher","year":"2015","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.critrevonc.2017.11.016_bib0525","doi-asserted-by":"crossref","first-page":"e2013037","DOI":"10.4084\/mjhid.2013.037","article-title":"Lenalidomide in combination with dexamethasone in elderly patients with advanced, relapsed or refractory multiple myeloma and renal failure","volume":"5","author":"Tosi","year":"2013","journal-title":"Mediterranean J. Hematol. Infect. Dis."},{"issue":"7","key":"10.1016\/j.critrevonc.2017.11.016_bib0530","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.3109\/10428194.2011.654116","article-title":"Efficacy of lenalidomide plus dexamethasone in patients older than 75 years with relapsed multiple myeloma","volume":"53","author":"Touzeau","year":"2012","journal-title":"Leukemia Lymphoma"},{"issue":"22","key":"10.1016\/j.critrevonc.2017.11.016_bib0535","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1182\/blood.V128.22.1151.1151","article-title":"Efficacy of daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients with 1\u20133 prior lines of therapy: updated analysis of POLLUX","volume":"128","author":"Usmani","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2017.11.016_bib0540","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2016-03-705210","article-title":"Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma","volume":"128","author":"Usmani","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2017.11.016_bib0545","series-title":"Summary of Product Characteristics","author":"Velcade","year":"2016"},{"key":"10.1016\/j.critrevonc.2017.11.016_bib0550","first-page":"A061202","article-title":"Alliance a phase I\/II study of pomalidomide, dexamethasone and ixazomib versus pomalidomide and dexamethasone for patients with multiple myeloma refractory to lenalidomide and proteasome inhibitor based therapy: phase I results","volume":"375","author":"Voorhees","year":"2015","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.critrevonc.2017.11.016_bib0555","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.critrevonc.2017.11.016_bib0560","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1124\/dmd.111.039164","article-title":"Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats","volume":"39","author":"Yang","year":"2011","journal-title":"Drug Metab. Dispos."},{"issue":"4","key":"10.1016\/j.critrevonc.2017.11.016_bib0565","doi-asserted-by":"crossref","first-page":"683","DOI":"10.3109\/10428194.2012.728597","article-title":"Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma","volume":"54","author":"Zhu","year":"2013","journal-title":"Leukemia Lymphoma"},{"issue":"6","key":"10.1016\/j.critrevonc.2017.11.016_bib0570","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1182\/blood-2015-10-646810","article-title":"Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma","volume":"127","author":"van de Donk","year":"2016","journal-title":"Blood"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842817302214?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842817302214?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T21:26:22Z","timestamp":1603488382000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842817302214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":114,"alternative-id":["S1040842817302214"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2017.11.016","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A question of class: Treatment options for patients with relapsed and\/or refractory multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2017.11.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}